Therapix Biosciences (TRPXD) Stock Price, News & Analysis

Company Overview

Therapix Biosciences Ltd. (OTCMKTS: TRPXD) is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative cannabinoid-based therapies for a range of central nervous system and inflammatory disorders. The company’s core pipeline features proprietary formulations of dronabinol, a synthetic form of tetrahydrocannabinol (THC), being investigated for the treatment of fibromyalgia and Tourette syndrome. In addition to its dronabinol programs, Therapix is advancing novel synthetic cannabinoid analogs with the potential to offer targeted relief for post-traumatic stress disorder (PTSD) and other anxiety-related conditions.

Founded in 2015 and headquartered in Petah Tikva, Israel, Therapix leverages a research-driven approach that integrates preclinical models with early-stage clinical trials. The company’s management team is led by Chief Executive Officer Asher Milgrom, whose previous experience spans over two decades in pharmaceutical business development and strategic partnerships. Under his leadership, Therapix has established collaborations with academic institutions and contract research organizations to accelerate its development timelines and optimize its formulations for patient-centric delivery.

Therapix serves markets in Israel, Europe and North America, aligning its regulatory strategy with evolving frameworks for cannabinoid therapeutics. The company’s commercialization strategy includes exploring licensing agreements and joint ventures to expand access to its pipeline candidates upon regulatory approvals. With a focus on unmet medical needs in neurology and psychiatry, Therapix Biosciences continues to build scientific evidence for its drug candidates while seeking strategic alliances to strengthen its global market reach.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: 900 shs
• Average Volume: 1,852 shs
• Market Capitalization: $299 thousand
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

TRPXD Stock Analysis - Frequently Asked Questions

How do I buy shares of Therapix Biosciences?

Shares of TRPXD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Pharmaceutical Preparations
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:TRPXD
• CIK: N/A
• Web: therapixbio.com
• Phone: 972 3 616 7055
• Fax: N/A
• Employees: 8
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.49
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.28 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 50,000
• Free Float: N/A
• Market Cap: $299 thousand
• Optionable: Not Optionable
• Beta: N/A